UNSPSC 51384525: Ibuprofen aluminum

This classification denotes a cyclooxygenase inhibitor with the molecular formula 2C13H17O2.Al.HO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D0YGZ1VO1B, chemically known as aluminium, hydroxybis(.alpha.-methyl-4-(2-methylpropyl)benzeneacetato-.kappa.o)-, but more generally known as ibuprofen aluminum, which bears US NIH Compound Identifier 16683040. European Medicines Agency schedules ibuprofen aluminum or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08098MIG.

Most nations, for tariff purposes, schedule ibuprofen aluminum under HS 29163990. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)[O-].CC(C)CC1CCC(CC1)C(C)C(=O)[O-].[OH-].[AL+3].

UNSPSC 51384525 Ibuprofen aluminum is a Commodity code that nominally describes a specific pain-relief pharmaceutical formulation; however, recent state and local solicitations tagged with this code show little activity directly aligned with ibuprofen procurement. The three most recent opportunities instead focus on naloxone distribution, direct-to-manufacturer prescription program design, and generic multi-source pharmaceutical contracting — none of which center on ibuprofen products. The code's abstract description does not match the concrete work state and local governments are currently buying under it, suggesting the code sees misclassification or that the recent opportunities represent a narrow slice of actual activity. State and local issuing bodies using pharmaceutical-related codes include health departments, state HHS commissions managing pharmacy benefit programs, and cooperative purchasing alliances such as MMCAP serving multiple state and local participants across jurisdictions.

Recent opportunities underscore activity in Florida, Texas, and the Minnesota-led multistate cooperative. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually, with a response deadline of July 26, 2023 and quarterly deliveries required. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026 to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 on January 20, 2026 for generic multi-source pharmaceuticals and OTC products across participating state and local facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness set for July 1, 2026. The code shows limited documented recent activity directly aligned to ibuprofen procurement; firms pursuing this commodity should expect misalignment between the UNSPSC label and actual pharmaceutical procurement focus areas.